ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1188

Initial Estimates of Efficacy of Intra-Articular 2.5% Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis: An Observational Proof-of-Concept Study

Marius Henriksen1,2, Anders Overgaard1 and Henning Bliddal3, 1The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark, 2Department of physical therapy, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark, 3The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

There is a draught of available effective treatments of knee osteoarthritis (OA) and tests of new therapies are needed. Polyacrylamide hydrogel (PAAG) is a non-toxic, non-degradable synthetic product, used for years in the augmentation of soft tissues. Animal studies have shown that intra-articular (IA) PAAG significantly alleviates lameness and joint effusion over 2 years among horses with OA. Thus, IA injection of PAAG may be a promising treatment for knee OA in humans, albeit with a need for scientific evaluation of efficacy and safety. The present study has been conducted to establish an initial estimate of effectiveness of IA injection of PAAG for the symptomatic treatment of knee OA.

Methods:

Patients with OA of the knee were invited into a prospective open-label cohort study. The patients received IA injection of 3 ml of PAAG (a proprietary 2.5% cross-linked PAAG manufactured by Contura International A/S) twice within 1 month. The WOMAC questionnaire was used to estimate efficacy, and was collected at baseline and after 4, 7 and 13 months. Efficacy was mainly estimated as a change from baseline for the WOMAC pain subscale after 4 months (Normalised to 0-100 points; 100 worst). WOMAC stiffness and WOMAC physical function were measured as secondary estimates of efficacy. The efficacy variables were analyzed using a mixed-effect model repeated measure approach without imputation of missing data. Sensitivity analyses were done using baseline observation carried forward imputation.

Results:

118 patients (62 females) received IA PAAG. Of these there were WOMAC data available from 81 after 4 months, 66 after 7 months, and 47 after 13 months. At baseline the mean WOMAC pain score was 43.7 (SD17.5). There were statistically significant reductions in WOMAC pain after 4 months (mean change -13.3 points [95% CI: -17.3 to -9.3]; P<.0001), which exceeds established minimal clinically important improvements margins of 9 points. Similar results were found in WOMAC stiffness and physical function (figure 1). The improvement was sustained throughout the observation period. In the sensitivity analyses the estimates were generally lower caused by the non-responder imputation approach (table 1).

Conclusion:

These results suggest beneficial effects of IA injection of a 2.5% PAAG on knee OA symptoms, even in the long term (1 year). This is promising but efficacy needs to be confirmed in a randomized study with adequate measures taken to reduce risk of bias.

Figure 1. Changes from baseline in WOMAC. No imputation of missing data.

Table 1. Sensitivity analyses of changes from baseline in WOMAC. Missing data imputed using BOCF technique.

 


Disclosure: M. Henriksen, None; A. Overgaard, None; H. Bliddal, AbbVie Inc., Roche, Pfizer, Lilly, 5.

To cite this abstract in AMA style:

Henriksen M, Overgaard A, Bliddal H. Initial Estimates of Efficacy of Intra-Articular 2.5% Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis: An Observational Proof-of-Concept Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/initial-estimates-of-efficacy-of-intra-articular-2-5-polyacrylamide-hydrogel-for-the-treatment-of-knee-osteoarthritis-an-observational-proof-of-concept-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/initial-estimates-of-efficacy-of-intra-articular-2-5-polyacrylamide-hydrogel-for-the-treatment-of-knee-osteoarthritis-an-observational-proof-of-concept-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology